A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC
Status:
Unknown status
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2, open-label, multicenter study of HS-10296 with dose escalation, dose
expansion and extension cohorts in locally advanced or metastatic non-small-cell lung cancer
(NSCLC) patients who have progressed following prior therapy with an epidermal growth factor
receptor(EGFR) tyrosine kinase inhibitor (TKI) agent. The study is designed to evaluate
safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of once-daily and orally
(PO) administered HS-10296. The overall study design is shown in the flow chart below, which
consists of 3 phases: dose escalation, dose expansion and extension cohort.